Show simple item record

dc.contributor.authorDizdar, Yavuz
dc.contributor.authorDarendeliler, Emin
dc.contributor.authorBilgic, Bilge
dc.contributor.authorSakar, Burak
dc.contributor.authorBasaran, Mert
dc.contributor.authorOnat, Haluk
dc.contributor.authorBavbek, Sevil
dc.contributor.authorOzger, Harzem
dc.contributor.authorBasaran, Gul Atalay
dc.contributor.authorAgaoglu, Fulya Yaman
dc.contributor.authorUstuner, Zeki
dc.date.accessioned2021-03-06T07:34:12Z
dc.date.available2021-03-06T07:34:12Z
dc.date.issued2007
dc.identifier.citationUstuner Z., Basaran M., Dizdar Y., Agaoglu F. Y. , Bilgic B., Sakar B., Basaran G. A. , Darendeliler E., Ozger H., Onat H., et al., "Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, cilt.213, ss.221-229, 2007
dc.identifier.issn0040-8727
dc.identifier.othervv_1032021
dc.identifier.otherav_dcd95155-0973-44dc-934b-14e63959c5a9
dc.identifier.urihttp://hdl.handle.net/20.500.12627/145537
dc.identifier.urihttps://doi.org/10.1620/tjem.213.221
dc.description.abstractUSTUNER, Z., BASARAN, M., DIZDAR, Y., AGAOGLu, F.Y., BILGic, B., SAKAR, B., BASARAN, G.A., DARENDELILER, E., OZGER, H., ONAT, H. and BAVBEK, S. Clinical Outcome of Rhadomyosarcoma in Adolescent and Adult Patients: Single Center Experience from Turkey. Tohoku J. Exp. Med., 2007, 213 (3), 221-229 - Rhabdomyosarcoma (RMS) is rare disease in adults (age >= 16 years). The data from randomized prospective trials are scarce; the clinical outcome of these patients seems poor with the currently available treatment strategies. In this study, we report a single institution's experience in the treatment of adult RMS. We reviewed the medical records of patients with RMS who were >= 16 years and have been treated in our institution between 1988 and 2003 retrospectively. We analyzed the survival outcome of these patients and the prognostic impact of clinical/ pathological factors on their survival. In total, 23 patients with RMS were identified. Median age was 26 years (range, 16-72 years). Majority of patients were male (n: 17, 73.9%), and had large tumors ( >= 5 cm, n: 13, 56.5%), localized disease (NO, MO, n: 12, 52.2%), and embryonal histology (n: 10, 43.5%). Median overall survival was 31.3 months, and the 3-year progress ion-free survival and overall survival rates were 19.9% and 34.94%, respectively. Patients with smaller tumors (< 5 cm) (p < 0.04), local disease (p < 0.01), and normal lactic dehydrogenase (LDH) level (p < 0.01) at the time of diagnosis were found to have better survival outcome. The tumor size, serum LDH level, and metastatic disease at the time of diagnosis are potential predictors of outcome in patients with adult RMS. Adult RMS is an aggressive disease with poor survival despite treatment. The data from prospective, randomized multicenter trials are necessary in order to improve the clinical outcome of adult RMS patients. - rhabdomyosarcoma; adult; lactic dehydrogenase; survival; adolescent (0 2007 Tohoku University Medical Press
dc.language.isoeng
dc.subjectTIP, GENEL & İÇECEK
dc.subjectTıbbi Ekoloji ve Hidroklimatoloji
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTIP, ARAŞTIRMA VE DENEYSEL
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.titleClinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey
dc.typeMakale
dc.relation.journalTOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
dc.contributor.department, ,
dc.identifier.volume213
dc.identifier.issue3
dc.identifier.startpage221
dc.identifier.endpage229
dc.contributor.firstauthorID185160


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record